**Core tip:** Solitary fibrous tumor is now considered as a fibroblastic mesenchymal neoplasm of intermediate biological potential, and it rarely occurs in the pancreas. Here, we report a case of malignant pancreatic solitary fibrous tumor with systemic metastasis, review the literature, and discuss its biological features, diagnosis, and prognosis evaluations.

INTRODUCTION
============

Solitary fibrous tumor (SFT), first described in 1870, was established as a pleural neoplasm by Klemperer and Rabin in 1931\[[@B1]\]. This tumor is commonly found in serosal membranes, the dura of the meninges, and deep soft tissues. It is now recognized as a type of fibroblastic mesenchymal neoplasm of intermediate biological potential characterized by the pathognomonic *NAB2-STAT6* gene fusion\[[@B2]\]. Only a few reports on malignant pancreatic SFT have been previously published. We present herein the first case of malignant pancreatic SFT with typical Doege-Potter syndrome and, hepatic and bone metastases.

CASE PRESENTATION
=================

Primary complaints
------------------

A 48-year-old man was admitted to our hospital with 1-year history of pancreatic and liver tumors. The tumors were accidentally found when the patient went to a local hospital after a sudden incidence of fainting. It is noteworthy that he reported of recurrent incidences of hypoglycemia, however, there was no history of any endocrine disease.

History of past illness
-----------------------

His medical history showed that he had been treated eight times for metastatic liver tumor by transcatheter arterial chemoembolization and once by radioactive seed implantation. Five years before presentation, he had undergone an excision of a tumor of the right pterygopalatine fossa.

Physical examination
--------------------

Physical examination showed no other positive findings except that the liver was enlarged and palpable.

Laboratory and imaging examinations
-----------------------------------

Laboratory investigations showed an abnormal hemogram, including hemoglobin of 123 g/L (reference range: 131-172 g/L), neutrophils 72.8% (reference range: 50%-70%) and lymphocytes 10.8% (reference range: 20%-40%). The results of liver and kidney function were normal. The levels of serum tumor markers (CEA, CA 19-9, CA 12-5, and AFP) were all within normal limits.

Computed tomography (CT) imaging of the abdomen showed a 4.7 cm well-defined mass located in the lower posterior part of the body of the pancreas (Figure [1A](#F1){ref-type="fig"}). Non-uniform enhancement was observed from the arterial to portal venous phase. Meanwhile, multiple nodules and masses of various sizes were seen in the liver (Figure [1B](#F1){ref-type="fig"}). The largest one was located in the segment VIII of the liver with a diameter of about 15.9 cm. No obvious dilatation of intrahepatic and extrahepatic bile ducts was observed.

![Computed tomography imaging of the abdomen. A: A 4.7 cm × 4.4 cm mass (white arrow) located in the body of pancreas. Non-uniform enhancement was observed from the arterial phase \[computed tomography (CT) value = 68 Hu\] to portal venous phase (CT value = 59 Hu); B: Numerous liver metastatic tumors (white arrows). Enhanced scanning showed irregular enhancement and the largest one located in segment VIII measured 15.9 cm.](WJCC-8-343-g001){#F1}

Pancreatic magnetic resonance (MR) imagining also confirmed a hypervascular tumor located in the body of the pancreas and multiple tumors located in the liver. Those tumors were hypointense on T1-weighted MR images and hyperintense on T2-weighted MR images.

For a complete preoperative evaluation, fluorine-18 fluorodeoxyglucose positron emission tomography/CT (^18^F-FDG PET/CT) was performed. Images from the PET/CT revealed that both the pancreatic and the metastatic liver lesions had an increased uptake of the tracer FDG. Besides, the thoracic and lumbar vertebrae, humerus, femur, scapulae, ribs, sacrum, and pelvis also showed heterogeneous FDG uptake (Figure [2](#F2){ref-type="fig"}).

![Systemic fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography scan. The positron emission tomography/computed tomography scan revealed an increased uptake of fluorodeoxyglucose in the liver and heterogeneous fluorodeoxyglucose uptake in multiple bones.](WJCC-8-343-g002){#F2}

Further diagnostic work-up
--------------------------

A liver biopsy guided by B-mode ultrasound confirmed that the tumor was an SFT/ hemangiopericytoma (Grade 2).

FINAL DIAGNOSIS
===============

The patient was eventually diagnosed with a malignant SFT of the pancreas with Doege-Potter syndrome and metastases to the liver and bone.

TREATMENT
=========

In order to improve the quality of life of the patient and control the growth of the mass, a distal pancreatectomy, involving the body and tail and splenectomy, was performed after a multidisciplinary discussion, and the metastatic neoplasm in the left lateral lobe of the liver was also resected.

OUTCOME AND FOLLOW-UP
=====================

On gross examination, the pancreatic specimen measured 15 cm × 6 cm × 2 cm, which contained two well-circumscribed non-encapsulated masses. The larger lesion measuring 6.5 cm × 5 cm, had a soft fleshy cut surface containing hemorrhagic and necrotic areas (Figure [3A](#F3){ref-type="fig"}). Another metastatic lesion located in the left lobe of the liver measured 14 cm × 12 cm × 4 cm with a pale-yellow cut surface (Figure [3B](#F3){ref-type="fig"}). All the resection margins were free of tumor. On histopathological examination, it was found that the tumor was composed of abundant heterogeneous spindle cells (Figure [4A](#F4){ref-type="fig"}). A localized area of necrosis (Figure [4B](#F4){ref-type="fig"}) was visualized and there were 4-5 mitotic figures (Figure [4C](#F4){ref-type="fig"}) per 10 high-power fields (HPFs). Immunohistochemical (IHC) analysis of the resected tumor revealed that the tumor cells were diffusely positive for STAT6 (Figure [4D](#F4){ref-type="fig"}), CD34, CD31, Bcl-2, cell proliferation marker Ki-67, PHH-3, and D2-40, and negative for glial fibrillary acidic protein, S100, smooth muscle actin (SMA), Desmin, delay of germination 1, CD117, and receptor tyrosine kinase. The proliferation index of Ki-67 was observed to be above 10%. The patient's postoperative recovery was uneventful. Furthermore, a transcatheter arterial chemoembolization procedure was also performed to eliminate the residual tumor of the right liver, and postoperative follow-up at 6 mo demonstrated good results (Figure [5](#F5){ref-type="fig"}).

![Photographs of cut surface of surgical specimens. A: A soft mass located in the body of pancreas. Hemorrhage and necrosis changes can be seen in the cut surface; B: The pale-yellow cut surface of the hepatic metastasis.](WJCC-8-343-g003){#F3}

![Photomicrographs of histologic and immunohistochemical staining. A: Various atypical spindled cells irregularly arranged in the stroma \[hematoxylin-eosin (HE) staining; magnification: ×50\]; B: Histologic demonstration of mitotic activity (HE staining; magnification: ×200); C: Presence of necrosis (HE staining; magnification: ×100); D: Immunohistochemical staining for STAT6 showed diffused positivity in tumor cells (magnification: ×100).](WJCC-8-343-g004){#F4}

![Timeline. A brief summary of the patient's medical history is presented. TACE: Transcatheter arterial chemoembolization.](WJCC-8-343-g005){#F5}

DISCUSSION
==========

SFTs are now considered to occur anywhere in the body, but the pancreatic fibrous tumor is still rarely recorded in the literature: only 22 cases have been reported since 1999 (Table [1](#T1){ref-type="table"}). The vast majority of the cases presented with benign features, and only one case was defined as being malignant, based on its histological features\[[@B3]\]. The case we present here, to our knowledge, is the first malignant pancreatic SFT with clinical and pathological evidence of liver and bone metastases.

###### 

Clinical features of pancreatic solitary fibrous tumors

  **Ref**.                        **Age/Sex**   **Chief complaint(s)**             **Size (cm)**   **Location**   **Arterial-CT**   **Venous-CT**    **T1-MRI**    **T2-MRI**     **Tumor marker**
  ------------------------------- ------------- ---------------------------------- --------------- -------------- ----------------- ---------------- ------------- -------------- ------------------
  Lüttges et al\[[@B13]\]         50/female     Incidental                         5.5             Body           Enhanced          Enhanced         NA            NA             Negative
  Chatti et al\[[@B14]\]          41/male       Abdominal pain                     13.0            Body           Enhanced          Enhanced         Hypointense   Hyperintense   Negative
  Gardini et al\[[@B15]\]         62/female     Abdominal pain                     3.0             Head           Enhanced          Enhanced         NA            NA             Negative
  Miyamoto et al\[[@B10]\]        41/female     Abdominal pain                     2.0             Head-body      Enhanced          Enhanced         NA            NA             Negative
  Kwon et al\[[@B16]\]            54/male       Incidental                         4.5             Body           Enhanced          Enhanced         Hypointense   Hyperintense   Negative
  Srinivasan et al\[[@B17]\]      78/female     Back pain, weight loss             5.0             Body           Enhanced          Enhanced         NA            NA             Negative
  Chetty et al\[[@B18]\]          67/female     Incidental                         2.6             Head           Enhanced          Enhanced         NA            NA             Negative
  Ishiwatari et al\[[@B19]\]      58/female     Incidental                         3.0             Head           Enhanced          Enhanced         Hypointense   Hyperintense   Negative
  Sugawara et al\[[@B20]\]        55/female     Incidental                         7.0             Head           Enhanced          Enhanced         Hypointense   Hyperintense   Negative
  Azadi et al\[[@B6]\]            57/male       Incidental                         3.1             Tail           Enhanced          Enhanced         Hypointense   Hyperintense   
  Santos et al\[[@B21]\]          40/male       Incidental                         3.0             Body           NA                NA               NA            NA             Negative
  Tasdemir et al\[[@B11]\]        24/female     Epigastric pain                    18.5            Head           Enhanced          Enhanced         NA            NA             Negative
  van der Vorst et al\[[@B22]\]   67/female     Abdominal pain                     2.8             Head           Enhanced          NA               NA            NA             Negative
  Chen et al\[[@B23]\]            49/female     Abdominal pain                     13.0            Head           Enhanced          Enhanced         NA            NA             Negative
  Hwang et al\[[@B24]\]           53/female     Incidental                         5.2             Head           Enhanced          Enhanced         Hypointense   Hyperintense   Negative
  Baxter et al\[[@B25]\]          54/female     Abdominal pain                     3.5             Head           NA                N.A              NA            NA             CEA, CA19-9
  Estrella et al\[[@B3]\]         52/female     Obstructive jaundice               15.0            Head           Hetero-geneous    Hetero-geneous   NA            NA             Negative
  Han et al\[[@B26]\]             77/female     Jaundice                           1.5             Head           Enhanced          Enhanced         Hypointense   Hyperintense   Negative
  Murakami et al\[[@B27]\]        82/male       Hypokalemia, hypertension, edema   6.0             Tail           Hetero-geneous    Hetero-geneous   Hypointense   Hyperintense   Negative
  Paramythiotis et al\[[@B28]\]   55/male       Abdominal pain                     3.6             Body           Enhanced          Enhanced         Hypointense   Hyperintense   Negative
  Spasevska et al\[[@B29]\]       47/male       Epigastric pain and jaundice       3.5             Head           Enhanced          Enhanced         N.A           N.A            CA19-9
  Oana et al\[[@B30]\]            73/male       Abdominal discomfort               7.5             Head           Enhanced          Enhanced         Hypointense   Hyperintense   Negative
  Current case                    48/male       Hypoglyce-mia                      6.5             Body           Enhanced          Enhanced         Hypointense   Hyperintense   Negative

CT: Computed tomography; MRI: Magnetic resonance imaging; NA: Not applicable.

Until now, there is no one comprehensive definition of malignant SFTs. According to the previous literature, abdominal pain is the most common presentation of clinical syndrome in a pancreatic SFT (10/22 cases, 45.45%), followed by an incidental abdominal mass (8/22 cases, 36.36%) and obstructive jaundice. Infrequently, patients may present with paraneoplastic syndromes. The clinical manifestations were commonly refractory and recurrent hypoglycemia, which is the main clinical characteristic of Doege-Potter syndrome. Increased secretion of a pro-hormone form of the insulin-like growth factor II has been confirmed to be the primary mechanism of hypoglycemia according to a study\[[@B4]\]. Han et al\[[@B5]\] reported that SFTs with Doege-Potter syndrome were often malignant. Our case showed typical features of Doege-Potter syndrome at the onset of disease and also the malignant features. However, these symptoms were non-specific.

Radiologically, homogeneous enhancement of the lesion in the arterial phase to portal venous phase on CT as well as low T1 signal intensity and high T2 signal intensity on magnetic resonance imaging can be observed in most of the cases\[[@B2]\]. The non-typical feature makes it difficult to distinguish SFTs from the other soft tissue tumors\[[@B6]\]. Particularly, it was reported that a malignant and larger tumor may present with hemorrhage, calcifications, cystic areas and so on\[[@B2]\]. A non-uniform enhancement was observed in the image examinations of our case that showed similar features.

Furthermore, although a higher FDG uptake on ^18^F-FDG PET/CT may be a sign of a malignant SFT, the diagnostic utility is still debatable due to its imperfect sensitivity\[[@B7]\]. However, in our case, the ^18^F-FDG PET/CT was useful in the differential diagnosis of benign and malignant SFTs and evaluation of clinical significance. Thus, ^18^F-FDG PET/CT examination is still a recommendation for the full evaluation of suspicious malignant tumors.

Recently, the *NAB2-STAT6* fusion gene was found to express a unique molecular feature in 100% of SFT cases\[[@B8]\]. Thus, compared with other conventional IHC markers like CD34, STAT6 has been proved to be more sensitive (98%) and specific (85%) for SFT. Furthermore, a previous study reported that a higher risk of SFT aggressive behavior may be associated with specific *NAB2-STAT6* fusion variants\[[@B9]\], which could be a biomarker for identifying the distinct molecular feature of malignant SFTs.

For pathologic features, grossly, the pancreatic SFTs range from 2.0-18.5 cm in diameter\[[@B10],[@B11]\]. Tumors are usually well-circumscribed with a fibrous pseudocapsule. The cut surface may show a wide range of patterns from firm, white to tan, and fleshy mass with hemorrhage, necrosis, or calcification usually presented in large or malignant cases\[[@B2]\]. Histologically, a typical "patternless pattern", *i.e*., various atypical spindled cells arrayed randomly within the stroma, can be seen in most cases (Table [2](#T2){ref-type="table"}). People have defined malignant SFTs based upon its special histologic features: ≥ 4 mitotic figures per 10 HPFs, necrosis or hemorrhage, increased cellularity, nuclear pleomorphism, and a large size (\> 10 cm). The histological results of our case meet these criteria and show high-grade malignant manifestations. However, a poor correlation with patients outcomes\[[@B12]\] has been seen as low validity in predicting the biological features of SFTs. Therefore, pathologists treat SFT as a neoplasm of intermediate biological potential. Furthermore, complete surgical resection is the mainstay of treatment for pancreatic SFTs and good results were reported (Table [2](#T2){ref-type="table"}). Unfortunately, almost no information has been provided concerning systemic treatments for malignant pancreatic SFTs. For this reason, a multidisciplinary discussion, especially with the participation of pathologists, is recommended before initiation of treatment procedures for patients with an advanced stage of the disease.

###### 

Immunohistochemical and histological features along with outcomes of pancreatic solitary fibrous tumors

  **Ref**.                        **Immuno-histochemistry (+)**                                       **Histology**                                            **Risk assessment**   **Treatment**                                           **Follow-up**
  ------------------------------- ------------------------------------------------------------------- -------------------------------------------------------- --------------------- ------------------------------------------------------- --------------------------------------------------
  Lüttges et al\[[@B13]\]         CD34, CD99, Bcl-2, vimentin                                         No necrosis or mitoses                                   Benign                Distal pancreatectomy                                   Alive and well (20 mo)
  Chatti et al\[[@B14]\]          CD34, CD99, Bcl-2, vimentin                                         "Regular spindle cells"                                  Benign                Enucleation                                             Died 3 d postoperatively due to complications
  Gardini et al\[[@B15]\]         CD34, CD99, Bcl-2, vimentin, smooth muscle actin (focal)            NA                                                       Benign                Traverso-longmire                                       Alive and well (16 mo)
  Miyamoto et al\[[@B10]\]        CD34, Bcl-2                                                         No necrosis or mitoses                                   Benign                Laparoscopic enucleation                                Alive and well (7 mo)
  Kwon et al\[[@B16]\]            CD34, CD99, vimentin                                                "Typical bland spindle cells"                            Benign                Median segmentectomy                                    NA
  Srinivasan et al\[[@B17]\]      CD34, Bcl-2                                                         \< 1 mitoses/10 HPFs, no necrosis                        Benign                Distal pancreatectomy                                   Alive and well (7 mo)
  Chetty et al\[[@B18]\]          CD34, CD99, Bcl-2                                                   No necrosis or mitoses                                   Benign                Whipple                                                 Alive and well (6 mo)
  Ishiwatari et al\[[@B19]\]      CD34, Bcl-2                                                         Necrosis, no mitoses                                     Benign                Pancreaticoduodenectomy                                 Alive and well (42 mo)
  Sugawara et al\[[@B20]\]        CD34                                                                No necrosis or mitoses                                   Benign                Pancreaticoduoden-ectomy                                NA
  Azadi et al\[[@B6]\]            CD34, Bcl-2, Ki67 \< 5%                                             No malignant features                                    Benign                Distal pancreatectomy                                   NA
  Santos et al\[[@B21]\]          CD34, beta-catenin                                                  No necrosis or mitoses                                   Benign                Partial pancreatectomy                                  NA
  Tasdemir et al\[[@B11]\]        CD34, Bcl-2, beta-catenin, vimentin, Ki67 \< 2%                     1-2 mitoses/10 HPFs                                      Benign                Enucleation                                             Alive and well (3 mo)
  van der Vorst et al\[[@B22]\]   CD34, CD99, Bcl-2                                                   No necrosis or mitoses                                   Benign                Enucleation                                             NA
  Chen et al\[[@B23]\]            CD34, Bcl-2, vimentin, CD68, muscle-specific actin                  Necrosis, no mitoses                                     Benign                Whipple                                                 Alive and well (30 mo)
  Hwang et al\[[@B24]\]           CD34, Bcl-2, muscle-specific actin, CD10, ER, PR                    "Spindle shaped cell with patternless cell deposition"   Benign                Duodenal preserving partial pancreatic head resection   Alive and well (30 mo)
  Baxter et al\[[@B25]\]          CD34, Bcl-2                                                         NA                                                       Benign                Whipple                                                 NA
  Estrella et al\[[@B3]\]         CD34, Bcl-2, keratin (rare), p16, p53                               Nuclear atypia, 17 mitoses/10 HPFs, necrosis             Malignant             Pancreaticoduoden-ectomy                                Alive and well (40 mo)
  Han et al\[[@B26]\]             CD34, CD99                                                          No necrosis or mitoses                                   Benign                Ultrasonography-guided needle biopsy                    No metastasis or changes in the size after 10 mo
  Murakami et al\[[@B27]\]        CD34, Bcl-2, STAT6, ACTH (focal), POMC (focal), NSE (focal)         "Spindle neoplastic cells in fascicular arrangement"     Benign                Distal pancreatectomy                                   Died 4 mo postoperatively due to sepsis
  Paramythiotis et al\[[@B28]\]   CD34, CD99, Bcl-2, vimentin, S100 (focal)                           No mitoses                                               Benign                Distal pancreatectomy                                   Alive and well (40 mo)
  Spasevska et al\[[@B29]\]       CD34, vimentin, CD99, Bcl-2 (focal), nuclear beta-catenin (focal)   No necrosis or mitoses                                   Benign                Whipple                                                 Died 1 wk postoperatively due to complications
  Oana et al\[[@B30]\]            CD34, Bcl-2                                                         No necrosis or mitoses                                   Benign                Partial pancreatectomy                                  Alive and well (36 mo)
  Current case                    CD34, Bcl-2, STAT6, CD31, PHH-3, D2-40 and Ki67 \> 10%              Necrosis, 4-5 mitoses/10 HPFs                            Malignant             Distal pancreatectomy and hepatic tumor resection       Alive and well (6 mo)

NA: Not applicable.

CONCLUSION
==========

In summary, we present a malignant pancreatic SFT with systemic metastasis and typical Doege-Potter syndrome features. The diagnosis and prognosis evaluation of malignant SFTs rely on more accurate criteria combined with clinical, IHC, and histological evidence. Furthermore, prospective studies are needed to provide greater evidence about the systemic management of malignant pancreatic SFTs.
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